Unraveling the Roles of CD44/CD24 and ALDH1 As Cancer Stem Cell Markers in Tumorigenesis and Metastasis

Overview

Journal Sci Rep

Specialty Science

Date 2017 Oct 25

PMID 29062075

Citations 206

Authors

Wenzhe Li

Huailei Ma

Jin Zhang

Ling Zhu

Chen Wang

Yanlian Yang

Affiliations

Soon will be listed here.

Abstract

CD44/CD24 and ALDH1 are widely used cancer stem cell (CSC) markers in breast cancer. However, their expression is not always consistent even in the same subtype of breast cancer. Systematic comparison of their functions is still lacking. We investigated the expression of CD44, CD24 and ALDH1 in different subtypes of breast cancer cells, and explored their relationship with cancer progression. We defined a parameter CD44/CD24 ratio to present the expression level of CD44 and CD24 and found that high CD44/CD24 ratio and ALDH1 are both indicators for cancer malignancy, but play different functions during tumor progression. High CD44/CD24 ratio is more related to cell proliferation and tumorigenesis, which is confirmed by mammosphere formation and tumorigenesis in xenotransplanted mice. ALDH1 is a stronger indicator for cell migration and tumor metastasis. Suppression of CD44 and ALDH1 by siRNA led to decreased tumorigenicity and cell migration capacity. The combination of high CD44/CD24 ratio and ALDH1 would be a more reliable way to characterize CSCs. Moreover, both high CD44/CD24 ratio and ALDH1 were conserved during metastasis, from the primary tumors to the circulating tumor cells (CTCs) and the distant metastases, suggesting the significant value of these CSC markers in assisting cancer detection, prognostic evaluation, and even cancer therapeutics.

Citing Articles

MELK as a Mediator of Stemness and Metastasis in Aggressive Subtypes of Breast Cancer.

McBean B, Abou Zeidane R, Lichtman-Mikol S, Hauk B, Speers J, Tidmore S Int J Mol Sci. 2025; 26(5).

PMID: 40076867 PMC: 11900306. DOI: 10.3390/ijms26052245.

Human Cytomegalovirus Infection and Breast Cancer: A Literature Review of Clinical and Experimental Data.

Blanco R, Munoz J Biology (Basel). 2025; 14(2).

PMID: 40001942 PMC: 11851556. DOI: 10.3390/biology14020174.

Development and Characterization of CD44-Targeted X-Aptamers with Enhanced Binding Affinity for Cancer Therapeutics.

Wang H, He W, Elizondo-Riojas M, Zhou X, Lee T, Gorenstein D Bioengineering (Basel). 2025; 12(2).

PMID: 40001633 PMC: 11852163. DOI: 10.3390/bioengineering12020113.

CD6 in Human Disease.

Gurrea-Rubio M, Fox D, Castresana J Cells. 2025; 14(4).

PMID: 39996744 PMC: 11853562. DOI: 10.3390/cells14040272.

Mechanism of action of genistein on breast cancer and differential effects of different age stages.

Xiang Z, Ma B, Pei X, Wang W, Gong W Pharm Biol. 2025; 63(1):141-155.

PMID: 39996512 PMC: 11864014. DOI: 10.1080/13880209.2025.2469607.

References

Sheridan C, Kishimoto H, Fuchs R, Mehrotra S, Bhat-Nakshatri P, Turner C . CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006; 8(5):R59. PMC: 1779499. DOI: 10.1186/bcr1610. View

Chute J, Muramoto G, Whitesides J, Colvin M, Safi R, Chao N . Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci U S A. 2006; 103(31):11707-12. PMC: 1544234. DOI: 10.1073/pnas.0603806103. View

He K, Xu T, Goldkorn A . Cancer cells cyclically lose and regain drug-resistant highly tumorigenic features characteristic of a cancer stem-like phenotype. Mol Cancer Ther. 2011; 10(6):938-48. PMC: 3112267. DOI: 10.1158/1535-7163.MCT-10-1120. View

Al-Hajj M, Wicha M, Benito-Hernandez A, Morrison S, Clarke M . Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-8. PMC: 153034. DOI: 10.1073/pnas.0530291100. View

Dalerba P, Cho R, Clarke M . Cancer stem cells: models and concepts. Annu Rev Med. 2006; 58:267-84. DOI: 10.1146/annurev.med.58.062105.204854. View

Glinsky G, Berezovska O, Glinskii A . Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005; 115(6):1503-21. PMC: 1136989. DOI: 10.1172/JCI23412. View

Ferro de Beca F, Caetano P, Gerhard R, Alvarenga C, Gomes M, Paredes J . Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types. J Clin Pathol. 2012; 66(3):187-91. DOI: 10.1136/jclinpath-2012-201169. View

Dent R, Trudeau M, Pritchard K, Hanna W, Kahn H, Sawka C . Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1):4429-34. DOI: 10.1158/1078-0432.CCR-06-3045. View

Kennecke H, Yerushalmi R, Woods R, Chon U Cheang M, Voduc D, Speers C . Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010; 28(20):3271-7. DOI: 10.1200/JCO.2009.25.9820. View

10.

Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G . Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res. 2006; 12(19):5615-21. DOI: 10.1158/1078-0432.CCR-06-0169. View

11.

Reya T, Morrison S, Clarke M, Weissman I . Stem cells, cancer, and cancer stem cells. Nature. 2001; 414(6859):105-11. DOI: 10.1038/35102167. View

12.

Nogi H, Suzuki M, Kamio M, Kato K, Kawase K, Toriumi Y . Impact of CD44+CD24- cells on non-sentinel axillary lymph node metastases in sentinel node-positive breast cancer. Oncol Rep. 2011; 25(4):1109-15. DOI: 10.3892/or.2011.1177. View

13.

Abraham B, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H . Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res. 2005; 11(3):1154-9. View

14.

Dong Y, Bi L, Xu N, Yang H, Zhang H, Ding Y . The expression of aldehyde dehydrogenase 1 in invasive primary breast tumors and axillary lymph node metastases is associated with poor clinical prognosis. Pathol Res Pract. 2013; 209(9):555-61. DOI: 10.1016/j.prp.2013.05.007. View

15.

Yang Z, Ngai P, Ho D, Yu W, Ng M, Lau C . Identification of local and circulating cancer stem cells in human liver cancer. Hepatology. 2008; 47(3):919-28. DOI: 10.1002/hep.22082. View

16.

Ring A, Mineyev N, Zhu W, Park E, Lomas C, Punj V . EpCAM based capture detects and recovers circulating tumor cells from all subtypes of breast cancer except claudin-low. Oncotarget. 2015; 6(42):44623-34. PMC: 4792580. DOI: 10.18632/oncotarget.5977. View

17.

Jordan C, Guzman M, Noble M . Cancer stem cells. N Engl J Med. 2006; 355(12):1253-61. DOI: 10.1056/NEJMra061808. View

18.

Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S . American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007; 25(33):5287-312. DOI: 10.1200/JCO.2007.14.2364. View

19.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View

20.

Fischer A, Jacobson K, Rose J, Zeller R . Hematoxylin and eosin staining of tissue and cell sections. CSH Protoc. 2011; 2008:pdb.prot4986. DOI: 10.1101/pdb.prot4986. View